A phase 3 clinical trial finds an anti-inflammatory drug used in rheumatoid arthritis can preserve lung function in patients with systemic sclerosis.
Osteopontin is discovered as the culprit behind these patients’ main cause of death. However, a repurposed immunosuppressive drug may combat the pro-inflammatory protein.
Successfully tested in mice, targeted drug and gene therapies might one day benefit patients with a deadly lung disease, new U-M research finds.
Michigan Medicine researchers sought to find out if they can anticipate who will be affected by psychiatric morbidity after surviving acute respiratory distress syndrome.